Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | The risk or severity of adverse effects can be increased when Resveratrol is combined with Apixaban. |
| Dasatinib | Dasatinib may increase the anticoagulant activities of Resveratrol. |
| Ursodeoxycholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of adverse effects can be increased when Resveratrol is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of adverse effects can be increased when Resveratrol is combined with Hyodeoxycholic Acid. |
| Glucosamine | Glucosamine may increase the antiplatelet activities of Resveratrol. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibritumomab tiuxetan. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Resveratrol is combined with Obinutuzumab. |
| Pentoxifylline | Pentoxifylline may increase the antiplatelet activities of Resveratrol. |
| Rivaroxaban | Resveratrol may increase the anticoagulant activities of Rivaroxaban. |
| Tipranavir | Tipranavir may increase the antiplatelet activities of Resveratrol. |
| Urokinase | Resveratrol may increase the anticoagulant activities of Urokinase. |
| Vitamin E | Vitamin E may increase the antiplatelet activities of Resveratrol. |
| Ibrutinib | The risk or severity of adverse effects can be increased when Ibrutinib is combined with Resveratrol. |
| Cilostazol | Cilostazol may increase the antiplatelet activities of Resveratrol. |
| Tofacitinib | The risk or severity of bleeding can be increased when Resveratrol is combined with Tofacitinib. |
| Zolmitriptan | The metabolism of Zolmitriptan can be decreased when combined with Resveratrol. |
| Warfarin | The risk or severity of bleeding can be increased when Resveratrol is combined with Warfarin. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Resveratrol is combined with Acenocoumarol. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Resveratrol is combined with (R)-warfarin. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Resveratrol is combined with (S)-Warfarin. |
| Tacrolimus | The risk or severity of bleeding can be increased when Resveratrol is combined with Tacrolimus. |
| Pentosan polysulfate | The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Resveratrol. |
| Limaprost | Limaprost may increase the antiplatelet activities of Resveratrol. |
| Omega-3 fatty acids | Omega-3 fatty acids may increase the antiplatelet activities of Resveratrol. |
| Tositumomab | The risk or severity of adverse effects can be increased when Resveratrol is combined with Tositumomab. |
| Pamidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Pamidronic acid. |
| Zoledronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Zoledronic acid. |
| Alendronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Alendronic acid. |
| Ibandronate | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Ibandronate. |
| Clodronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Clodronic acid. |
| Risedronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Risedronic acid. |
| Etidronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Etidronic acid. |
| Tiludronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Tiludronic acid. |
| Incadronic acid | The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Incadronic acid. |
| Lepirudin | The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding can be increased when Resveratrol is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Alteplase. |
| Reteplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding can be increased when Resveratrol is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding can be increased when Resveratrol is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding can be increased when Resveratrol is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding can be increased when Resveratrol is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding can be increased when Resveratrol is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding can be increased when Resveratrol is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding can be increased when Resveratrol is combined with Fondaparinux. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Resveratrol is combined with Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding can be increased when Resveratrol is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding can be increased when Resveratrol is combined with Epoprostenol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Resveratrol is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Resveratrol is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding can be increased when Resveratrol is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding can be increased when Resveratrol is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding can be increased when Resveratrol is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding can be increased when Resveratrol is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding can be increased when Resveratrol is combined with Prasugrel. |
| Sulodexide | The risk or severity of bleeding can be increased when Resveratrol is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding can be increased when Resveratrol is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding can be increased when Resveratrol is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding can be increased when Resveratrol is combined with Astaxanthin. |
| Otamixaban | The risk or severity of bleeding can be increased when Resveratrol is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding can be increased when Resveratrol is combined with Amediplase. |
| Danaparoid | The risk or severity of bleeding can be increased when Resveratrol is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Tinzaparin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Resveratrol is combined with Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding can be increased when Resveratrol is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding can be increased when Resveratrol is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding can be increased when Resveratrol is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding can be increased when Resveratrol is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding can be increased when Resveratrol is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding can be increased when Resveratrol is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding can be increased when Resveratrol is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding can be increased when Resveratrol is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding can be increased when Resveratrol is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding can be increased when Resveratrol is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding can be increased when Resveratrol is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding can be increased when Resveratrol is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding can be increased when Resveratrol is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding can be increased when Resveratrol is combined with Darexaban. |
| Betrixaban | The risk or severity of bleeding can be increased when Resveratrol is combined with Betrixaban. |